The anticancer peptide PNC-27, which contains an HDM-2-binding domain corresponding to residues 12-26 of p53 and a transmembrane-penetrating domain, has been found to kill cancer cells (but not normal cells) by inducing membranolysis. We find that our previously determined 3D structure of the p53 residues of PNC-27 is directly superimposable on the structure for the same residues bound to HDM-2, suggesting that the peptide may target HDM-2 in the membranes of cancer cells. We now find significant levels of HDM-2 in the membranes of a variety of cancer cells but not in the membranes of several untransformed cell lines.
In colocalization experiments, we find that PNC-27 binds to cell membrane-bound HDM-2. We further transfected a plasmid expressing full-length HDM-2 with a membrane-localization signal into untransformed MCF-10-2A cells not susceptible to PNC-27 and found that these cells expressing full-length HDM-2 on their cell surface became susceptible to PNC-27. We conclude that PNC-27 targets HDM-2 in the membranes of cancer cells, allowing it to induce membranolysis of these cells selectively.
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We have found previously that the peptide PNC-27, containing the HDM-2-binding domain of p53, residues 12-26, attached to a transmembrane-penetrating or membrane residency peptide (MRP) on its carboxyl terminal end, and PNC-28 (p53 residues 17-26-MRP) induce tumor cell necrosis by forming pores in cancer cell membranes but have no effects on a number of untransformed cells, including human stem cells from cord blood (1) (2) (3) (4) , and eradicate tumors in nude mice (5) . The p53-HDM-2 complex results in the catabolism of p53 (6) .
In contrast, other studies using HDM-2-binding molecules including p53 peptides attached to membrane-penetrating sequences on their amino terminal ends and small molecules that block the p53-HDM-2 interaction found that these agents induce p53-dependent apoptosis of cancer cells (6) (7) (8) (9) (10) (11) . However, our observations were consistent with the results from a 2D NMR study on the structure of PNC-27 showing that this peptide adopts a strongly amphipathic alpha-helix-loop-alpha-helix structure (12) observed in membrane-active peptides (13, 14) . While this study suggested the basis of their lytic action, it did not explain why these peptides lyse the membranes of cancer cells selectively.
Because these peptides contain sequences that are known to bind to HDM-2 in its amino terminal domain, residues 1-109 (15), we now investigate whether they interact with HDM-2 that may be expressed in the membranes of transformed but not untransformed cells.
Results
Superposition of the 2D NMR Structures of the HDM-2-Binding Domain of PNC-27 on the X-Ray Structure of the Isolated Peptide Bound to HDM-2. In our prior 2D NMR determination of the solution structure of PNC-27, we obtained 30 structures that fit the NOE constraints (12) . When we superimposed these structures on the x-ray structure, all superimposed closely, giving a range of rms deviations of 1.7-2.5 Å. Fig. 1 shows the superposition for the backbone atoms of the structure of lowest rms deviation on the x-ray structure. This agreement occurs despite the fact that the x-ray structure contains a "truncated" peptide beginning at residue 17 and is bound to HDM-2 while PNC-27 contains six additional amino terminal residues (p53 residues 12-16) and Leu 26 attached to the transmembrane-penetrating sequence, not present on the peptide used in the x-ray crystal structure. We conclude that residues 17-26 of PNC-27 fold into a native HDM-2-binding conformation.
Cytotoxicity of PNC-27 to Cancer Cells. We tested PNC-27 against the cancer cell lines used in this study. As shown in Fig. S1 , we found that PNC-27, but not control PNC-29 peptide, is cytotoxic to MIA-PaCa-2 cells, inducing 100% cell death in 90 min and MIA-PaCa-2, TUC-3, and A-2058 cells in a dose-related manner but did not affect untransformed AG13145 primary human fibroblasts. Previously, we found that PNC-27 kills MCF-7 cells by a nonapoptotic (16) mechanism (2).
Blotting for HDM-2 in Cancer Cell Membranes. To test whether cancer cells express HDM-2 in their cell membranes, we isolated the membrane fractions (confirmed by electron microscopy) and whole cell lysates from several different cancer and untransformed cell lines shown in Fig. 2 and blotted them for HDM-2. On the lower panel for the blots in Fig. 2 , it can be seen that all whole cell lysates blot positively for HDM-2. On the upper panel for the blots in Fig. 2 , the membrane fraction of each cancer cell line (lanes 4-7) is seen to contain significant levels of HDM-2. In contrast, the three untransformed cell lines (lanes 1-3) were found to have low levels of HDM-2 in their membrane fractions. The percentage of whole cell lysate of HDM-2 present in the membrane fractions of the cell lines is shown in the bar graph (lowermost in Fig. 2 ). It can be seen that the fractions present in the membranes of the cancer cell lines are fourfold to ninefold increased over those for the untransformed cells. It should be noted that the HDM-2 bands shown in Fig. 2 were the major band at 92kDa. However, several other less prominent bands of lower Mr representing variants of HDM-2 were also observed in the membrane fractions of cancer cells that were absent in the three untransformed cell lines. We are currently investigating the identity of these variant forms. In other control experiments, we blotted the membrane fractions and whole cell lysates of each cell line for p53 and found that none of the membrane fractions contained this protein while it was present in the cell lysates. Our results suggest that HDM-2 is expressed in the membranes of cancer cells but only minimally in those of untransformed cells. Colocalization of PNC-27 with HDM-2 in the Cancer Cell Membrane.
We obtained further evidence for the interaction of PNC-27 with HDM-2 in cancer cell membranes by incubating PNC-27 with two different cancer cell lines, A2058 and MCF-7, and then incubating the cells with FITC-(green-fluorescent-) labeled anti-PNC-27 and TAMRA-(red-fluorescent-) labeled anti-HDM-2. We then viewed the cells using confocal microscopy. Colocalization of PNC-27 with HDM-2 in the cell membrane should result in concurrent green-and red-fluorescent signals from the two antibodies, presenting as yellow fluorescence in the cell membrane.
As shown in Fig. 4 A, A-2058 cells treated with PNC-27 show strong green (PNC-27, DO1 antibody) and red (HDM-2) fluorescence uniquely in the membrane of these cells; the latter result confirms the results of Fig. 2 . In the third frame of Fig. 4 A, there is pronounced yellow fluorescence in the membrane, suggesting colocalization. Fig. 4 B shows identical results for MCF-7 cells treated with PNC-27. In control experiments, we found that incubation with DO1 antibody to PNC-27/p53 of both cell lines that were not treated with PNC-27 did not show green fluorescence in the cell membrane, indicating that p53 was not present in this fraction. Treatment of two untransformed cell lines, i.e., BMRPA1 and MCF-10-2A, with PNC-27 followed by incubation with the two labeled antibodies resulted in identical patterns of fluorescence in which green fluorescence was diffusely distributed throughout the cells, suggesting that the peptide entered the cells without being held in the membrane, whereas there was no red fluorescence in their membranes, confirming our findings in Susceptibility of Transfected Cells to PNC-27. We further plated each set of transfected cells and treated each with PNC-27 for 24 hr. As shown in Fig. 6 , the cells expressing membrane-bound HDM-2-CVVK are induced to release LDH over twice the background value for untreated or empty-vector-transfected cells, and none of the other control cells were found to release LDH above this background value. We also observed a major decrease in cell viability only in the full-length HDM-2-CVVK-expressing cells (Fig. S2A ). This decrease was threefold compared with that for untreated cells and almost threefold compared with that for empty-vector-transfected controls. It was also at least 2.5-fold reduced compared with the cell viability of cells expressing HDM-2 on their membranes but lacking the binding site for HDM-2 despite the presence of HDM-2 in the cell membrane fraction (Fig. S2A) . None of these sets of cells was induced to undergo apoptosis as revealed by the absence of enhanced caspase activity above background (Fig. S2B) , consistent with our prior findings that PNC-27 induces tumor cell necrosis and not apoptosis (1) (2) (3) (4) (5) . Control peptide PNC-29 (200 μg∕ml), had no effect on either LDH release or the viability of any of the four sets of transfected cells, suggesting that PNC-27 binds specifically to HDM-2 on the cell membrane, allowing for its cytotoxicity.
Discussion
Our present studies suggest that PNC-27 induces cancer cell cytotoxicity by a previously undescribed mechanism in which the peptide induces cancer cell membranolysis that appears to depend on the binding of the peptide to HDM-2 in the cancer cell membrane. HDM-2 is present in the membranes of four different cancer cell lines but is only minimally present in the membranes of three different untransformed cell lines, providing a rationale for the specificity of action of this peptide. These observations are consistent with the results of prior studies on HDM-2 expression in mammalian cells. HDM-2is overexpressed in fast-growing tumors, and the levels of expression of HDM-2 correlated with metastatic potential in primary tumor cell cultures from patients with breast cancer (18) . Importantly, HDM-2 was found to colocalize with E-cadherin in the cancer cells' plasma membranes and to induce its ubiquitination and subsequent degradation, leading to increased cancer cell motility (18) . This latter study suggests that HDM-2 is expressed in the membranes of cancer cells and points to a functional role for its presence in the cell membrane.
Binding of PNC-27 to HDM-2 in Cell Membranes Is Critical to its
Membranolytic Action. That PNC-27 interacts with membranebound HDM-2 is supported by our confocal microscopy studies on PNC-27-treated cancer cells that show that PNC-27 colocalizes with HDM-2 in the membranes of these cells to which PNC-27 is lethal, a phenomenon that does not occur with untransformed cells that do not express HDM-2 in their membranes and that are not affected by PNC-27.
PNC-27 does not kill MCF-10-2A cells (2) . However, transfected cells that express full-length HDM-2-CVVK in their membranes become susceptible to the action of this peptide. In contrast, cells expressing either full-length HDM-2 that does not localize to the cell membrane or HDM-2 that does localize to the cell membrane but does not contain the p53 (PNC-27)-binding domain are much less susceptible to the action of this peptide. These results suggest that the membranolytic action of PNC-27 requires its interaction with HDM-2 in the cancer cell membrane. Similar results to ours have been reported in another study in which plasmid-driven overexpression of MDM-2 in rodent cardiomyocytes rendered these cells susceptible to PNC-28 (19) .
Unique Membranolytic Action of PNC-27 May be Due to Its MembraneActive Conformation. Using double fluorophore-labeled PNC-27 (as in Fig. 3) , we found that the peptide remains intact during tumor cell membranolysis (20) . In solution, PNC-27 adopts a membrane-active conformation in which the HDM-2-binding subdomain adopts the x-ray HDM-2-binding conformation. If the membrane-active conformation is retained when the peptide binds to HDM-2 in the cell membrane, then the peptide would remain membrane-active and form pores in the cancer cell membrane, as has been found to occur for other membrane-active peptides (14, 21) . When double fluorophore-labeled PNC-27 is incubated with untransformed cells, a small amount of peptide remains in the cell membrane while only the amino terminal domain is found in the nucleus, i.e., the carboxyl terminus is absent, EV is empty vector; HDM-2 is overexpressed HDM-2; HDM-2 þ CAAX is fulllength HDM-2 with the membrane-targeting CVVK sequence on the carboxyl terminus; del1-109 HDM-2 þ CAAX is HDM-2 without its p53 (PNC-27)-binding domain, residues 1-109, attached on its C terminus to the CVVK membrane-localization sequence. signifying peptide cleavage in the cell (20) . This pattern was also found in the colocalization experiments for untransformed cells incubated with PNC-27 (Fig. 4 D) . Interestingly, agents, like p53 peptides, that block p53-HDM-2 binding do not induce apoptosis in untransformed cells (4, (6) (7) (8) (9) (10) (11) . Thus it appears that HDM-2 in the cell membrane blocks the transit of PNC-27 into the cell, allowing it to remain in the membrane where it can undergo pore formation.
This hypothesis can explain why other agents, including small molecules like the nutlins (11) , that bind to HDM-2 competitively with p53 in cancer cells, and therefore should also bind to HDM-2 in the cell membrane, induce apoptosis, and not necrosis, of these cells. These agents would not be expected to adopt membrane-active conformations. This includes HDM-2-binding peptides that contain membrane-penetrating sequences on their amino terminal ends (8-10), which we previously found are much less alpha-helical (1) and therefore are not likely to adopt membrane-active conformations.
Materials and Methods
Materials. Peptides. PNC-27, H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-AspLeu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-LysVal-Gln-Arg-Gly-OH (1 g), was synthesized using solid phase methods (Shaanxi Zhongbang Pharma-Tech Corp., NanguanZhengjie, Xi'an, China) and was >95% pure by HPLC and mass spectrographic analysis. The bold sequence corresponds to amino acid residues 12-26 of the HDM-2-binding domain of human p53 while the italicized sequence corresponds to the MRP segment that allows entry of the whole peptide into cells. PNC-28, which contains p53 residues 17-26 linked to the MRP, was likewise synthesized by solid phase methods. The negative control peptide, PNC-29 (1-5), containing the X13 peptide from cytochrome P450 (bold) attached to the MRP (italics), H-Met-Pro-Phe-Ser-Thr-Gly-Lys-Arg-Ile-Met-Leu-Gly-Glu-Lys-Lys-Trp-Lys-MetArg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH, was likewise synthesized by solid phase methods and was likewise >95% pure.
FITC-and TAMRA-double fluorophore-labeled PNC-27 peptide. This peptide was synthesized at the Biopeptide Corp., La Jolla, CA, with two fluorescent labels: amino terminal 5,6-carboxy-fluorescein (green fluorescence) and carboxyl terminal 5-tetramethyl Rhodamine (TAMRA) (red fluorescence) and was found to be >95% pure (20) .
Plasmids. Untransformed cells that do not express HDM-2 in their cell membranes are not susceptible to PNC-27 (1-5). To determine if these cells become susceptible to this peptide if they contain HDM-2 in their cell membranes, we have transfected into these cells a plasmid that expresses full-length HDM-2 attached on its carboxyl terminal end to a CAAX localization signal peptide sequence, i.e., Cys-Val-Val-Lys (CVVK), called HDM-2-CVVK. The plasmid was a Precision ShuttleVector with a green fluorescent protein (GFP) tag and a specified open reading frame sequence, in our case, HDM-2-CVVK (Origene, Rockville, MD). Full-length HDM-2 with the carboxyl terminal CAAX sequence, called pHDM2-CVVK, was inserted into this plasmid between Sgf1 and Mlu 1 endonuclease restriction sites. Both the HDM-2 construct and GFP were under a constitutive CMV expression promoter that also induced expression of amp and neo resistance genes.
In addition to this plasmid, we prepared two other plasmids encoding proteins that served as controls: full-length HDM-2 without the CAAX sequence, called pHDM2 and HDM-2-CVVK, that lacks amino acid residues 1-109 that constitute the binding site for p53 and for PNC-27, called pdel1-109-HDM2-CVVK. All plasmids were prepared at Origene. The following primers were employed to construct the DNA sequences encoding each of the HDM-2 proteins. For these sequences all nuclease sites are given in bold; the start (ATG) and stop (TTA) codons are italicized; and the carboxyl terminal codons for the membrane-localization signal sequence, CVVK (CAAX box), are underlined: Full-length HDM-2:
CTACAGCGATCGCCATGGTGAGGAGCAGGCAAATGTGC ( After digestion with the cloning restriction enzyme Sgf-I and Mlu I, the PCR products were cloned into the Origene Precision Shuttle plasmid pCMV6-AN-GFP with an N-terminal fused GFP-tag. Final constructs were sequenced with VP1.5 5′ GGACTTTCCAAAATGTCG 3′ AND XL39 5′ ATTAGGACA AGGCTGGTGGG 3′ primers.
Cell lines. The following cell lines were obtained from the American Type (Molecular Probes, Invitrogen, Carlsbad, CA) and examined with a laserequipped Olympus Confocal microscope 1 × 76 (Olympus America Inc, Center Valley, PA). Results were digitally recorded. The colocalization of the two antibodies was confirmed by overlapping green (anti-PNC-27) and red (antiH/R/MDM-2) fluorescent labels that produced yellow fluorescence (combined green and red fluorescence).
Dose response experiments. LDH assays were performed on different cancer cell lines (n ¼ 3-5) that were incubated for 30 min with PNC-27 over a concentration range of 10 μg:ml∕1 mg∕ml as described previously (2-4).
Transfection of HDM-2 constructs into untransformed cells. The plasmids that were constructed as described in Materials above were transfected into untransformed MCF-10-2A cells using the procedures described previously (4). The transfection efficiency was evaluated by analyzing the GFP fluorescence at 480 nm.
Treatment of transfected cells with PNC-27 or PNC-29. The transfected cells in media were then incubated at 37°C with 5% CO 2 for 24 h, at which time they were treated with PNC-27 or PNC-29 peptide (sonicated briefly prior to addition) such that the final concentration was 300 μg∕ml. Samples were assayed for LDH, MTT, and caspase. In addition, samples were processed for confocal microscopy as described above except for the following modification. Because the cells contained GFP, to localize PNC-27, it was necessary to use another fluorescent probe other than green-fluorescent FITC-labeled DO1 antibody. Cells were incubated with unlabeled DO1 and anti-HDM-2 as described above. The cells were then washed and incubated with Alexa Fluor 647 goat antimouse IgG (1∶200) (against DO1 mouse) (Invitrogen-Molecular Probe, Eugene, OR) and TAMRA-labeled goat antirabbit IgG (1∶200) (against anti-HDM-2 rabbit polyclonal IgG) (Sigma, St. Louis, MO). The cells were processed for confocal microscopy, and the membrane fractions and whole cell lysates were blotted for either HDM-2 or actin [rabbit anti-actin-42 polyclonal antibody (1∶5000)] (Sigma).
